Diabetic Peripheral Neuropathy Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Status | Recruiting |
Enrollment | 410 |
Est. completion date | January 31, 2025 |
Est. primary completion date | January 17, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening. - Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) =10 at time of screening. - Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history. - Have a visual analog scale (VAS) pain value =40 and <95 during screening. - Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for =6 months and diagnosed by a score of Part B =3 on Michigan Neuropathy Screening Instrument - Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. - Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study - Have a body mass index =45 kilogram/square meter (kg/m²) (inclusive). - Are men, or women able to abide by reproductive and contraceptive requirements. Exclusion Criteria: - History of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP. - Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques. - Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. - Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide. - Have in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. - Have a positive HIV test result at screening. - Have a surgery planned during the study for any reason. - Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association) |
Country | Name | City | State |
---|---|---|---|
Czechia | EDUMED - Broumov | Broumov | Královéhradecký Kraj |
Czechia | Vestra Clinics | European Union | Rychnov Nad Knežnou |
Czechia | Agentura Science Pro | Olomouc | |
Czechia | FLEDIP s.r.o. | Prague | Praha, Hlavní Mešto |
Czechia | Diabet2 s.r.o., diabetologicka a interni ambulance | Praha | Praha 1 |
Czechia | Neurologická Ambulance - Forbeli | Praha | Praha 6 |
Czechia | DiaVize s.r.o. | Praha 4 | Praha, Hlavní Mešto |
Japan | Japanese Red Cross Asahikawa Hospital | Asahikawa | Hokkaido |
Japan | Kunisaki Makoto Clinic | Fukuoka | |
Japan | Kure Medical Center | Kure | Hiroshima |
Japan | Kikuchi Naika Clinic | Maebashi | Gunma |
Japan | Matsuyama Shimin Hospital | Matsuyama | Ehime |
Japan | Medical Corporation Sato Medical clinic | Ootaku | Tokyo |
Japan | Minamiosaka Hospital | Osaka | |
Japan | Heishinkai Medical Group ToCROM Clinic | Shinjuku-ku | Tokyo |
Japan | Plumeria DM Clinic | Shizuoka | |
Japan | Suruga Clinic | Shizuoka-city | Shizuoka |
Japan | Sugiura Internal Medicine Clinic | Sokashi | Saitama |
Japan | Medical Corporation Heishinkai OCROM Clinic | Suita-shi | Osaka |
Japan | Yokohama Minoru Clinic | Yokohama | Kanagawa |
Korea, Republic of | Eulji University Hospital | Daejeon | Taejon-Kwangyokshi |
Korea, Republic of | Jeonbuk National University Hospital | Jeonju-si | Jeonrabugdo |
Korea, Republic of | Konkuk University Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Nowon Eulji Medical Center, Eulji University | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Samsung Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Sejong General Hospital | Sosa-gu | Kyonggi-do |
Poland | Osteo Medic sc A. Racewicz, J. Supronik | Biaystok | Podlaskie |
Poland | Centrum Medyczne Pratia Katowice | Katowice | Slaskie |
Poland | Pro Familia Altera | Katowice | Slaskie |
Poland | NZOZ Diab-Endo-Met | Krakow | Malopolskie |
Poland | Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna | Lodz | Lódzkie |
Poland | Nzoz Neuro-Kard Ilkowski i Partnerzy SPL | Poznan | Wielkopolskie |
Poland | NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki | Ruda Slaska | Slaskie |
Poland | MICS Centrum Medyczne Torun | Torun | Kujawsko-pomorskie |
Poland | Medycyna Kliniczna | Warszawa | Mazowieckie |
Poland | Centrum Badan Klinicznych Piotr Napora lekarze sp.p. | Wroclaw | Dolnoslaskie |
Poland | Samodzielny Publiczny Zespol Opieki Zdrowotnej w Wyszkow | Wyszkow | Mazowieckie |
United States | FutureSearch Trials of Neurology | Austin | Texas |
United States | Northwest Clinical Research Center | Bellevue | Washington |
United States | Hope Clinical Research, Inc. | Canoga Park | California |
United States | Northwestern University | Chicago | Illinois |
United States | UniMed Center | East Brunswick | New Jersey |
United States | CMR of Greater New Haven, LLC | Hamden | Connecticut |
United States | Lucas Research, Inc. | Hickory | North Carolina |
United States | Juno Research | Houston | Texas |
United States | The Center for Pharmaceutical Research | Kansas City | Missouri |
United States | New Phase Research and Development | Knoxville | Tennessee |
United States | Care Access - Lake Charles | Lake Charles | Louisiana |
United States | Las Vegas Medical Research | Las Vegas | Nevada |
United States | Alliance for Multispecialty Research, LLC | Lexington | Kentucky |
United States | Preferred Research Partners | Little Rock | Arkansas |
United States | Velocity Clinical Research, Medford | Medford | Oregon |
United States | The Institute for Liver Health dba Arizona Clinical Trials | Mesa | Arizona |
United States | New Horizon Research Center | Miami | Florida |
United States | Suncoast Research Group | Miami | Florida |
United States | Lucas Research, Inc | Morehead City | North Carolina |
United States | Valley Clinical Trials, Inc. | Northridge | California |
United States | Tristar Clinical Investigations | Philadelphia | Pennsylvania |
United States | North Suffolk Neurology | Port Jefferson Station | New York |
United States | Rainier Clinical Research Center | Renton | Washington |
United States | SKY Clinical Research Network Group-Quinn | Ridgeland | Mississippi |
United States | Northern California Research - Sacramento | Sacramento | California |
United States | StudyMetrix Research | Saint Peters | Missouri |
United States | Headlands Research - Scottsdale | Scottsdale | Arizona |
United States | Consano Clinical Research, LLC | Shavano Park | Texas |
United States | Clinvest Research LLC | Springfield | Missouri |
United States | Synexus Clinical Research US, Inc.//Orange Grove Family Practice | Tucson | Arizona |
United States | MedVadis Research Corporation | Waltham | Massachusetts |
United States | Suburban Research Associates | West Chester | Pennsylvania |
United States | Velocity Clinical Research, Salt Lake City | West Jordan | Utah |
United States | Alliance for Multispecialty Research, LLC | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States, Czechia, Japan, Korea, Republic of, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS) | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Worst Pain Intensity Numeric Rating Scale (WPI-NRS) | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form (SF)8a | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Pain Interference with Sleep | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for PROMIS Physical Functioning Short Form (SF)10a | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for PROMIS Sleep Disturbance (SD)8b | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Patient's Global Impression of Illness (PGI) Severity as Measured by PGI-Severity | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Patient's Global Impression of Illness Status as Measured by PGI-Status | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Patient's Global Impression of Change as Measured by PGI-Change | Baseline, Week 12 | ||
Secondary | Mean Change from Baseline for Neuropathy Total Symptom Score-6 (NTSS-6) | Baseline, Week 12 | ||
Secondary | Summary of Frequency, Timing and Amount of Rescue Medication Used During the Treatment Period | Baseline to Week 12 | ||
Secondary | Pharmacokinetics (PK): Plasma Concentration of LY3556050 | Baseline to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04638556 -
Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
|
||
Completed |
NCT05580705 -
Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy
|
N/A | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT00835757 -
Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT00553592 -
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
|
Phase 2 | |
Recruiting |
NCT05863793 -
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT05041816 -
Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04457531 -
LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy
|
Early Phase 1 | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02056431 -
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01681290 -
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01474772 -
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
|
Phase 3 | |
Completed |
NCT01086150 -
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03447756 -
Titration Study of ABX-1431
|
Phase 1 | |
Completed |
NCT04688671 -
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT04984044 -
Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms
|
N/A | |
Completed |
NCT06130917 -
Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN.
|
N/A | |
Completed |
NCT01496365 -
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT02332005 -
12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study
|
Phase 2/Phase 3 |